Camber Pharmaceuticals celebrated its 15th anniversary in 2022. The company had 44 ANDA approvals and successfully launched 28 new generic products into the pharmaceutical market. While overcoming many obstacles caused by the global pandemic, Camber established and introduced a new specialty division with a focus on injectables and oncology drugs.
28 New Products in 2022
Camber launched 28 new prescription products in 2022, setting a record for product introductions in a single year for the organization.
“We had many important launches in 2022, including multiple Day-One products that help dramatically reduce the cost of life-saving medications while addressing some major shortages in the US market,” said Camber President Kon Ostaficiuk.
44 ANDA Approvals – A Strong Pipeline
Hetero, Camber’s parent company, is committed to expanding and diversifying its product portfolio to address the growing demand for high-quality, affordable generic medications. In 2022, Hetero received 44 new ANDA approvals and anticipates even more success in 2023.
Camber Specialty Expands Our Therapeutic Categories
Early in 2022, Camber Specialty was established to focus on specialty pharmaceutical products, including injectable medications and generic oncology drugs. Some recent studies have indicated that two-thirds of all new drug launches will be classified as “specialty” products in 2023.
Our OTC Offers Are Growing
Camber Consumer Care also experienced many successes this year. It launched three new products, increased capacity on six key products and provided private-label services to some of the country’s largest retailers. Camber Consumer Care’s products focus on allergy, pain and gastrointestinal relief products.
Investments That Impact Customers, Patients, and Associates
In 2022, Camber invested in multiple programs focused on providing benefits for Camber’s customers, patients, and associates. The organization established a Copay Coupon Program on key products to help offset the cost to patients, completed the transition to the New Warehouse and Headquarters to accommodate business growth and added numerous team members to the warehouse, customer service, finance, and operations teams.
High Expectations for 2023
In 2023, the company plans to launch even more products than in 2022, including new prescription medications, specialty products and OTC drugs.
“We will invest more in developing our associates, perfecting our processes and bringing more high-quality, affordable medications to our customers and patients in 2023,” added Camber President Kon Ostaficiuk.
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dosage manufacturers. Camber is committed to bringing the highest-quality generic pharmaceuticals to consumers, improving their quality of life through cost-effective medications.
- Camber Pharmaceuticals Launches Generic Namenda®
- 28 New Generics in 2022 and Anticipates Record Number of Approvals in 2023
- Camber Pharmaceuticals Launches Generic Cambia®
- Camber Pharmaceuticals Launches Generic Kuvan® Tablets and Powder for Oral Solution
- Camber Pharmaceuticals Launches Generic Vimpat® Injection
- Camber Pharmaceuticals Launches Generic Naprosyn®